uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
June 21, 2023 07:05 ET
|
uniQure Inc.
~ AMT-130 continues to be generally well-tolerated across both dose cohorts ~ ~ Patients treated with AMT-130 show preserved function compared to baseline and clinical benefits relative to natural...
uniQure announces achievement of $100 million milestone related to hemophilia B gene therapy
June 20, 2023 07:05 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, June 20, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 16, 2023 07:05 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, June 16, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
Viral Vector Market is expected to hit USD 2.13 Bn by 2029 at a CAGR of 19.7 percent – says Maximize Market Research
May 19, 2023 07:47 ET
|
MAXIMIZE MARKET RESEARCH PRIVATE LIMITED
Pune, May 19, 2023 (GLOBE NEWSWIRE) -- Maximize Market Research, a globally recognized healthcare research and business consulting firm, has recently published an extensive market intelligence...
uniQure Announces Sale of Royalty Interest in HEMGENIX® for Up To $400 Million
May 15, 2023 07:05 ET
|
uniQure Inc.
~ uniQure to receive $375 million upfront cash payment ~ ~ Under the existing agreement with CSL Behring, uniQure retains the rights to future milestones totaling up to $1.5 billion and maintains an...
uniQure Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 09, 2023 07:05 ET
|
uniQure Inc.
~ Clinical update from U.S. Phase I/II trial in Huntington’s disease expected in second quarter 2023 ~ ~ Continued progress towards initiating two new Phase I/II clinical studies for AMT-260 in...
uniQure Announces Major Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 02, 2023 16:40 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, May 02, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2023 07:05 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, May 02, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
Global Gene Therapy Market Report 2023: Major Players Include Novartis, Bluebird Bio, Spark Therapeutics, Audentes Therapeutics and Voyager Therapeutics
April 06, 2023 05:13 ET
|
Research and Markets
Dublin, April 06, 2023 (GLOBE NEWSWIRE) -- The "Gene Therapy Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report provides strategists, marketers and...
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 13, 2023 07:05 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 13, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...